HC Wainwright Expects Lower Earnings for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for TG Therapeutics in a research report issued on Monday, August 3rd. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings of $0.27 per share for the quarter, down from their previous estimate of $0.28. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $1.46 per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2026 earnings at $0.86 EPS and FY2027 earnings at $2.16 EPS.

Other analysts have also recently issued research reports about the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $83.00 price target on shares of TG Therapeutics in a report on Monday, June 22nd. B. Riley Financial lifted their price target on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. Bank of America boosted their target price on shares of TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research note on Wednesday, July 29th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $58.50.

TG Therapeutics Price Performance

TGTX opened at $46.17 on Tuesday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81. The stock has a market capitalization of $7.07 billion, a PE ratio of 16.14, a price-to-earnings-growth ratio of 1.30 and a beta of 1.62. The stock’s 50 day moving average price is $50.62 and its 200-day moving average price is $39.07. TG Therapeutics has a 52-week low of $25.28 and a 52-week high of $59.30.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The firm had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.TG Therapeutics’s revenue was up 70.2% on a year-over-year basis. During the same period last year, the business earned $0.17 EPS.

Institutional Investors Weigh In On TG Therapeutics

A number of large investors have recently made changes to their positions in TGTX. Royal Bank of Canada boosted its position in shares of TG Therapeutics by 16.4% in the first quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock worth $2,985,000 after purchasing an additional 10,660 shares during the period. NewEdge Advisors LLC grew its position in shares of TG Therapeutics by 9.6% during the first quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock valued at $299,000 after purchasing an additional 665 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of TG Therapeutics by 21.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock worth $75,683,000 after buying an additional 345,059 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in TG Therapeutics by 5.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock worth $11,319,000 after acquiring an additional 14,689 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of TG Therapeutics by 86.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 573 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

Key Stories Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: BRIUMVI sales exceeded expectations. Second-quarter global revenue reached approximately $240 million, including about $228 million in U.S. BRIUMVI net product revenue—up 64% year over year and above the roughly $230 million total-revenue consensus. TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
• Positive Sentiment: Management raised its 2026 outlook. TG Therapeutics now expects approximately $950 million in total 2026 revenue, ahead of the approximately $942 million consensus estimate, and increased its U.S. BRIUMVI revenue target to approximately $890 million-$905 million. The CEO also said BRIUMVI remains on track to become a $1 billion U.S. product. TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
• Positive Sentiment: Future growth opportunities remain. The company’s planned subcutaneous BRIUMVI formulation could broaden the multiple sclerosis market and potentially improve margins, with Phase 3 data expected in late 2026 or early 2027. TG Therapeutics: Why I’m Staying Long After The Q2 Selloff
• Neutral Sentiment: Revenue growth was strong, rising 70.2% from the prior-year quarter, and some investors appeared willing to look past the earnings miss because of BRIUMVI’s commercial momentum.
• Negative Sentiment: Quarterly EPS fell short of expectations. TG Therapeutics reported adjusted earnings of $0.05 per share, versus consensus estimates ranging from $0.31 to $0.41 and $0.17 a year earlier. Manufacturing investments weighed on profitability, creating near-term concern despite the improved sales outlook. TGTX Q2 Earnings Lag, Sales Rise Year Over Year, 2026 View Raised

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.